Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Department of Biobehavioral Health Sciences, School of Nursing, University of Pennsylvania, Philadelphia, PA 19104, USA.
Sci Transl Med. 2020 Mar 4;12(533). doi: 10.1126/scitranslmed.aay8071.
The glucagon-like peptide-1 receptor (GLP-1R) agonist liraglutide is approved for the treatment of obesity; however, there is still much to be learned regarding the neuronal sites of action that underlie its suppressive effects on food intake and body weight. Peripherally administered liraglutide in rats acts in part through central GLP-1Rs in both the hypothalamus and the hindbrain. Here, we extend findings supporting a role for hindbrain GLP-1Rs in mediating the anorectic effects of liraglutide in male rats. To dissociate the contribution of GLP-1Rs in the area postrema (AP) and the nucleus tractus solitarius (NTS), we examined the effects of liraglutide in both NTS AAV-shRNA-driven knockdown and AP-lesioned animals. Knockdown of NTS GLP-1Rs, but not surgical lesioning of the AP, attenuated the anorectic and body weight-reducing effects of acutely delivered liraglutide. In addition, NTS c-Fos responses were maintained in AP-lesioned animals. Moreover, NTS knockdown was sufficient to attenuate the intake- and body weight-reducing effects of chronic daily administered liraglutide over 3 weeks. Development of improved obesity pharmacotherapies requires an understanding of the cellular phenotypes targeted by GLP-1R agonists. Fluorescence in situ hybridization identified transcripts in NTS GABAergic neurons, which when inhibited using chemogenetics, attenuated the food intake- and body weight-reducing effects of liraglutide. This work demonstrates the contribution of NTS GLP-1Rs to the anorectic potential of liraglutide and highlights a phenotypically distinct (GABAergic) population of neurons within the NTS that express the GLP-1R and are involved in the mediation of liraglutide signaling.
胰高血糖素样肽-1 受体 (GLP-1R) 激动剂利拉鲁肽已被批准用于治疗肥胖症;然而,对于其抑制食物摄入和体重的作用的神经元作用部位,仍有许多需要了解。在大鼠中,外周给予的利拉鲁肽部分通过下丘脑和后脑的中枢 GLP-1R 起作用。在这里,我们扩展了支持后脑 GLP-1R 在介导利拉鲁肽对雄性大鼠的厌食作用的发现。为了区分后穹窿 (AP) 和孤束核 (NTS) 中 GLP-1R 的贡献,我们检查了利拉鲁肽在 NTS AAV-shRNA 驱动的敲低和 AP 损伤动物中的作用。NTS GLP-1R 的敲低,但不是 AP 的手术损伤,减弱了急性给予利拉鲁肽的厌食和体重减轻作用。此外,AP 损伤动物的 NTS c-Fos 反应得以维持。此外,NTS 敲低足以减弱慢性每日给予利拉鲁肽 3 周的摄食量和体重减轻作用。开发更好的肥胖症治疗药物需要了解 GLP-1R 激动剂针对的细胞表型。荧光原位杂交鉴定了 NTS GABA 能神经元中的 转录本,当使用化学遗传学抑制这些转录本时,减弱了利拉鲁肽的摄食量和体重减轻作用。这项工作证明了 NTS GLP-1R 对利拉鲁肽的厌食潜力的贡献,并突出了 NTS 中表达 GLP-1R 并参与利拉鲁肽信号转导的表型不同(GABA 能)神经元群体。